Drug Trial Radar · NCT05682170
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Dec 1, 2022
Primary completion
Jul 2, 2024
Study completion Jul 26, 2024
Sponsor
- Lead sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
ZN-d5 ZN-c3Drug
Oral agent
ZN-c3Drug
Oral agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed dose limiting toxicitiesTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Incidence, severity, and relatedness of adverse events( AEs)Time frame: Through study completion, typically < 12 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California San Francisco
San Francisco, California
Dana Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
NYU Langone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Albert Einstein College of Medicine - Montefiore Medical Center
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Tristar Bone Marrow Transplant
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
The Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.